Valuation
- Market cap
- 62,160,000
- Revenue TTM
- $0
- Net income TTM
- $-116,800,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 164,900
- Avg volume
- 181,750
- Day's range
- $6.50 – $6.82
- Shares out
- 9,361,000
- Stochastic %K
- 8%
- Beta
- 1.62
- Analysts
- Strong Sell
- Price target
- $34.83
Company profile
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edite...
Show more
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 503 9095
- Website
- https://www.adicetbio.com
- Address
- 131 Dartmouth Street, 3rd Floor, Boston, United States
Latest news
No headlines yet.
